Balaji Amines Reports Consolidated Q4FY26 Revenue of ₹ 403 Crore Amid Strong Operational Gains

Balaji Amines Reports Consolidated Q4FY26 Revenue of ₹ 403 Crore Amid Strong Operational Gains​

Solapur, May 13, 2026: Balaji Amines Limited, a prominent manufacturer of Aliphatic Amines and Specialty Chemicals in India, has announced its audited financial results for the quarter and year ended March 31, 2026. The company specializes in manufacturing Methyl Amines, Ethyl Amines, Derivatives of Amines, and various Specialty Chemicals.

The financial results show strong operational momentum, with consolidated Q4FY26 revenue reaching ₹ 403 Crore, and consolidated Net Profit standing at ₹ 65 Crore.

Financial Performance Overview​

The company's performance across key financial metrics for the quarter and the full fiscal year is detailed below.


***

Operational Highlights for Q4FY26​

The Revenue from Operations for Q4FY26 stood at ₹ 403 crore, marking a notable increase compared to ₹ 361 crore recorded in Q3FY26, reflecting stable operational performance of approximately 12%.

Total volumes achieved for Q4 FY26 reached 27,341 MT, up from 25,872 MT in Q4 FY25. The growth in revenue was primarily attributed to commodity prices and sustained demand across major segments.

For the fourth quarter alone, the company reported:

• Amines volumes at 7,746 MT.
• Amines Derivatives volumes at 8,935 MT.
• Specialty Chemicals volumes at 10,660 MT.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) for Q4FY26 was ₹ 102 crore, compared to ₹ 68 crore in Q4FY25. The EBITDA margin for Q4FY26 stood at 25%, an improvement from 19% reported in Q4FY25. Net Profit After Tax (PAT) for Q4FY26 was ₹ 65 crore.

Strategic Expansion and New Projects​

Balaji Amines continues to advance its strategic priorities with multiple projects both under execution and commissioning plans.

Key Projects Under Development:

• DME Plant at Unit-IV: This plant is anticipated for commissioning in the First Quarter of FY 2026-27. Its applications span the Aerosol industry, besides serving as a replacement for LPG usage in Industrial and Commercial sectors.
• N-Methyl Morpholine (NMM): A 5000 TPA NMM facility is currently under execution, with expected commissioning during FY 2026-27.
• Acetonitrile: An improved process based ACN plant is also under execution, slated for commissioning in the Second Quarter of FY 2026-27.

Major Investments:
The company is investing in a wide range of products through a new expansion of Rs. 750 crores at its subsidiary, Balaji Speciality Chemicals Limited. This investment scope includes Hydrogen Cyanide (HCN), Sodium Cyanide (NaCN) 30% (Solution), Sodium Cyanide (NaCN) 100% (Pellets), Ethylene Diamine Tetra Acetic Acid (EDTA), and Ethylene Diamine Tetra Acetic Acid Disodium Salts (EDTA-2Na).

The company also has several planned unit upgrades:

• Unit-I: A brown field project for EDA based products, adding a reactor to manufacture value added products such as DETA, TETA, PIP, AEEA, and AEP, is expected to be commissioned during the first half of FY 2026-27.
• Unit-II (Greenfield Project): Works for erecting and installing equipment are ongoing, targeting the manufacture of HCN, NaCN, EDTA, and EDTA-2Na. These are expected to be operational during Q4 of FY 2026-27.

Management Commentary​

Mr. D. Ram Reddy, Managing Director, highlighted the company's resilience during the quarter and year ending March 31, 2026. He stated that despite a temporary external disruption in March 2026 due to a geopolitical situation, the company successfully mitigated the impact through careful inventory planning and maintained stable plant operations.

The fourth quarter performance solidified the company's integrated manufacturing model and execution capabilities. While demand in some end-user industries remained steady, the established businesses in amines, derivatives, and specialty chemicals provided stable operations.

Mr. Reddy added that the focus going into the new fiscal year remains on improving plant utilization, enhancing operating leverage, and maintaining disciplined execution. He stated that the combination of a resilient business plan, a growing specialty chemicals portfolio, and emerging export opportunities positions Balaji Amines for a gradual ramp-up of operations.

About Balaji Amines Limited​

Established in 1988, Balaji Amines Limited is a leading manufacturer of Aliphatic Amines in India. The company specializes in manufacturing Methyl Amines, Ethyl Amines, Derivatives of Aliphatic Amines, and Specialty Chemicals, with its business classified into three segments: Amines, Specialty Chemicals, and Derivatives. It services diverse industries including Pharmaceuticals, Agro Chemicals, Paint Stripping & Resins, and Rubber cleaning chemicals. The company maintains four manufacturing sites and is recognized as a leader in Specialty Chemicals among international players.

BALAMINES Stock Price Movement​

Shares of Balaji Amines Limited are surging today, up 18.55% as of 12:12 PM, pushing the equity to ₹1603.9 on a ₹251.00 gain. This robust rally is supported by strong market conviction, evidenced by a significant total traded volume of 1.54 million shares.